ABIVAX Société Anonyme

NasdaqGM:ABVX Stock Report

Market Cap: US$8.1b

ABIVAX Société Anonyme Management

Management criteria checks 3/4

ABIVAX Société Anonyme's CEO is Marc M. de Garidel, appointed in May 2023, has a tenure of 3.08 years. total yearly compensation is €1.15M, comprised of 52.3% salary and 47.7% bonuses, including company stock and options. directly owns 0.58% of the company’s shares, worth $47.05M. The average tenure of the management team and the board of directors is 3 years and 4.9 years respectively.

Key information

Marc M. de Garidel

Chief executive officer

€1.1m

Total compensation

CEO salary percentage52.30%
CEO tenure3.1yrs
CEO ownership0.6%
Management average tenure3yrs
Board average tenure4.9yrs

Recent management updates

Recent updates

Seeking Alpha • 9h

Abivax: Safety Signals Loom Ahead Of The NDA Submission

Summary ABIVAX reported best-in-class maintenance efficacy potential for obefazimod in ulcerative colitis (UC), but dose-dependent malignancy signals cloud commercial prospects. ABVX plans NDA submission for obefazimod in Q4 2026, with Crohn’s disease Phase 2b data delayed to mid-2027. Cash runway based on its burn rate presents a financial risk. Statistically significant dysplasia/malignancy risk was observed at the 50mg dose; further analyses reveals malignancy rates are higher than what is expected, raising regulatory and valuation concerns. Despite ~$3 billion+ sales potential for its lead indication in UC, the market may be prudent to remain cautious due to safety signals, regulatory uncertainty, and lack of acquisition activity. Obefazimod is in a class of relatively underdeveloped and underexplored groups of compounds that present safety risks, including one reported patient death. Read the full article on Seeking Alpha
Seeking Alpha • Mar 27

ABIVAX: Undercovered, Late-Stage French Company With Upcoming Catalysts

Summary ABIVAX is a French company that IPO-ed in the US in 2023 and is running a phase 3 trial for ulcerative colitis. Their lead candidate, obefazimod, is in phase 3 trials for moderate to severe ulcerative colitis and has a novel mechanism of action. The company faces competition from other approved treatments for ulcerative colitis, but their drug has shown promising efficacy and a good safety profile. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has Marc M. de Garidel's remuneration changed compared to ABIVAX Société Anonyme's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-€332m

Dec 31 2025€1m€601k

-€336m

Sep 30 2025n/an/a

-€294m

Jun 30 2025n/an/a

-€195m

Mar 31 2025n/an/a

-€186m

Dec 31 2024€631k€578k

-€176m

Sep 30 2024n/an/a

-€185m

Jun 30 2024n/an/a

-€177m

Mar 31 2024n/an/a

-€165m

Dec 31 2023€794k€359k

-€148m

Compensation vs Market: Marc M.'s total compensation ($USD1.32M) is below average for companies of similar size in the US market ($USD8.37M).

Compensation vs Earnings: Marc M.'s compensation has increased whilst the company is unprofitable.

CEO

Marc M. de Garidel (68 yo)

3.1yrs
Tenure
€1,148,314
Compensation

Mr. Marc M. P. de Garidel, M.B.A., serves as Director of Claris Biotherapeutics, Inc. He has been CEO at ABIVAX Société Anonyme since May 5, 2023 and serves as its Director. He had been Interim Chair of th...

Leadership Team

NamePositionTenureCompensationOwnership
Marc M. de Garidel
CEO & Director3.1yrs€1.15m0.58%
$ 47.0m
Didier Blondel
EVP, CFO & Board Secretary9.4yrsno data0.00047%
$ 38.0k
Patrick Malloy
Senior Vice President of Investor Relations2.8yrsno datano data
Ida Hatoum
Chief People & Compliance Officer3yrsno datano data
Pierre Courteille
Chief Business Officerno datano data0%
$ 0
Jerome Denis
Executive Vice President of Process Development & Manufacturing2.8yrsno datano data
Hema Keshava
Senior Vice President of Financeno datano datano data
Chris Rabbat
VP & Global Head of Medical Affairsno datano datano data
Kevin Shan
VP & Global Head of Biometricsno datano datano data
Mary Mantock
Senior VP & Global Head of Regulatory Affairsno datano datano data
Douglas Jacobstein
Senior VP & Global Head of Clinical Developmentno datano datano data
Nadege Briancon-Eris
Global Head of Development Operations & SVPno datano datano data
3.0yrs
Average Tenure
59.5yo
Average Age

Experienced Management: ABVX's management team is considered experienced (3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Marc M. de Garidel
CEO & Director3.1yrs€1.15m0.58%
$ 47.0m
Sylvie Gregoire
Independent Chair of the Board1.9yrs€143.75kno data
Christian Brechot
Member of Scientific Advisory Board8.7yrsno datano data
Christian Trepo
Member of Scientific Advisory Boardno datano datano data
Lawrence Stanberry
Member of Scientific Advisory Boardno datano datano data
Troy Ignelzi
Independent Director2.9yrs€128.75k0%
$ 0
Christoph Huber
Member of Scientific Advisory Boardno datano datano data
Claude Bertrand
Member of Scientific Advisory Board6.7yrs€4.94kno data
Luc Teyton
Member of Scientific Advisory Boardno datano datano data
June H. Lee
Independent Director2.9yrs€127.50k0%
$ 0
Corinna Bonsen-Thomas
Independent Non-Executive Director9yrs€115.00k0%
$ 0
Ian McGowan
Chairman of Scientific Advisory Board8yrsno datano data
4.9yrs
Average Tenure
65.5yo
Average Age

Experienced Board: ABVX's board of directors are considered experienced (4.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/17 15:41
End of Day Share Price 2026/06/17 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ABIVAX Société Anonyme is covered by 21 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Etzer DaroutBarclays
Julian HarrisonBTIG
Jason ButlerCitizens JMP Securities, LLC